Latest Capital Raising News

Dome Gold Mines has updated the schedule for its Share Purchase Plan, setting new dates for offer opening, closing, and share issuance through September 2025. This move aligns with ongoing development efforts at its Fiji-based mining projects.

Vital Metals Limited has had its trading suspension lifted following announcements addressing an ASX Price and Volume Query and a new capital raise, signaling renewed market activity.

Vital Metals Limited has clarified the recent spike in its share price and trading volume, attributing it to a confidential capital raise and a positive scoping study amid a broader rare earths sector rally.

360 Capital Group (ASX – TGP) reported a 15% rise in operating profit for FY25 and announced a substantial $78.8 million special distribution, reflecting strong momentum in its real estate and credit platforms.

InhaleRx Limited reported a widening half-year loss as it accelerates clinical trials for inhaled drug-device therapies, supported by a substantial $38.5 million funding facility.

360 Capital Group has reported a significant profit increase for FY25 alongside a stable dividend and a substantial $0.40 per security special distribution, reflecting strong cash reserves and strategic growth in real estate credit.

G50 Corp has raised A$10 million through a well-supported institutional placement to fund extensive drilling and metallurgical testing at its Golconda project in Arizona, targeting strategic minerals including gallium.

Legacy Minerals has secured NSW Government approval to recommence drilling at its Mt Carrington gold-copper project, unveiling fresh geophysical targets and backed by a recent $7.75 million capital raise.

Dome Gold Mines has announced a $5 million Share Purchase Plan at a 6.25% discount to fund critical milestones for its Sigatoka Sands Project in Fiji, aiming to secure a mining licence and commence operations.

WAM Microcap Limited reported a robust 27% increase in net profit for FY2025, driven by strong portfolio returns and sustained dividend payments. The company’s investment strategy continues to outperform the market, underpinning an optimistic outlook for micro-cap equities.

Otto Energy has appointed industry veteran Chris Dorros as CEO, signaling a strategic push to leverage his two decades of upstream energy expertise. The move aligns with Otto’s growth ambitions and shareholder value focus.

Neuren Pharmaceuticals has initiated the first US investigational site for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, marking a significant milestone in addressing this rare neurodevelopmental disorder.